SYGNIS Licenses Amplification Buffer to QIAGEN
Complete the form below to unlock access to ALL audio articles.
Spanish-German biotech company SYGNIS Pharma AG has signed a licence agreement for the distribution of a new amplification buffer with QIAGEN. This is the first licence agreement for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.
The recently granted licence covers a new amplification buffer, a tool used in isothermal amplification, providing superior reaction performance.
“With the new agreement, SYGNIS adds a global reference in the sector in the fields of DNA amplification research and commercial markets. This newly signed agreement shows that SYGNIS is making progress in the commercialization of core technologies and products designed for the DNA sequencing and amplification market. It strengthens the network of relationships we maintain with life science and diagnostics companies in the DNA amplification industry,” SYGNIS’ CEO Pilar de la Huerta commented.
Background
In July 2012, through X-POL, SYGNIS reached an exclusive global licence agreement with QIAGEN for the distribution of the polymerase QualiPhi®.
QualiIPhi® is an upgraded version of phi 29 DNA polymerase. Compared to similar polymerase proteins on the market, the new one exhibits enhanced properties. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, among other applications.
Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are basic in research involving analysis and modification of DNA from any species.
